World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
95
Citations
52715
World Ranking
9865
National Ranking
5072

Overview

Peter J. O'Dwyer is affiliated with the University of Pennsylvania in the United States. Their research spans multiple areas within medicine and biomedical sciences, with a strong focus on oncology and molecular biology. Over their career, they have contributed extensively to academic literature in these fields.

The scientist has published research in the following fields of study:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

Within these areas, their subfields of study include:

  • Oncology
  • Molecular Biology
  • Pulmonary and Respiratory Medicine
  • Cancer Research
  • Surgery

O'Dwyer's main research topics cover a wide range of cancer-related subjects:

  • Cancer Genomics and Diagnostics
  • Pancreatic and Hepatic Oncology Research
  • Colorectal Cancer Treatments and Studies
  • Lung Cancer Treatments and Mutations
  • Gastric Cancer Management and Outcomes
  • PI3K/AKT/mTOR signaling in cancer
  • Chronic Lymphocytic Leukemia Research

Their publication record includes contributions to significant journals, with frequent publications in:

  • Journal of Clinical Oncology
  • JCO Precision Oncology
  • Clinical Cancer Research
  • Cancer Research
  • Annals of Oncology

Among recent papers authored or coauthored by O'Dwyer are:

  • "Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)", 2020, Journal of Clinical Oncology
  • "Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H", 2020, Journal of Clinical Oncology
  • "Service Robots in the Healthcare Sector", 2021, Robotics
  • "Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211)", 2022, Journal of Clinical Oncology
  • "Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W", 2020, Journal of Clinical Oncology

O'Dwyer has collaborated frequently with other researchers, including:

  • Stanley R. Hamilton
  • Lyndsay N. Harris
  • Keith T. Flaherty
  • Lisa M. McShane
  • Robert J. Gray

Best Publications

  • Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

    Daniel J. Klionsky;Kotb Abdelmohsen;Akihisa Abe;Joynal Abedin

  • Inhibition of mutated, activated BRAF in metastatic melanoma.

    Keith T. Flaherty;Igor Puzanov;Kevin B. Kim;Antoni Ribas

  • Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

    Bruce J. Giantonio;Paul J. Catalano;Neal J. Meropol;Peter J. O'Dwyer

  • CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans

    Gregory L. Beatty;Elena G. Chiorean;Matthew P. Fishman;Babak Saboury

  • Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

    Mark J. Ratain;Tim Eisen;Walter M. Stadler;Keith T. Flaherty

  • High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis.

    Andrew K. Godwin;Alton Meister;Peter J. O'Dwyer;Chin Shiou Huang

  • Vitamin D Receptor-Mediated Stromal Reprogramming Suppresses Pancreatitis and Enhances Pancreatic Cancer Therapy

    Mara H. Sherman;Ruth T. Yu;Dannielle D. Engle;Ning Ding

  • Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

    Daniel J. Klionsky;Kotb Abdelmohsen;Akihisa Abe;Joynal Abedin

  • Phase II Trial of Sorafenib in Advanced Thyroid Cancer

    Vandana Gupta-Abramson;Andrea B. Troxel;Anoma Nellore;Kanchan Puttaswamy

  • Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.

    Scott Kopetz;Jayesh Desai;Emily Chan;Joel Randolph Hecht

  • Clinical Activity and Immune Modulation in Cancer Patients Treated With CP-870,893, a Novel CD40 Agonist Monoclonal Antibody

    Robert H. Vonderheide;Keith T. Flaherty;Magi Khalil;Molly S. Stumacher

  • Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.

    Gerald S Falchook;Karl D Lewis;Jeffrey R Infante;Michael S Gordon

  • Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (fixed-dose rate infusion) Compared With Gemcitabine (30-minute infusion) in Patients With Pancreatic Carcinoma E6201: A Trial of the Eastern Cooperative Oncology Group

    Elizabeth Poplin;Yang Feng;Jordan Berlin;Mace L. Rothenberg

  • Combined-Modality Treatment for Resectable Metastatic Colorectal Carcinoma to the Liver: Surgical Resection of Hepatic Metastases in Combination With Continuous Infusion of Chemotherapy—An Intergroup Study

    M. Margaret Kemeny;Sudeshna Adak;Bruce Gray;John S. Macdonald

  • Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer

    Roy S. Herbst;S. Gail Eckhardt;Razelle Kurzrock;Scot Ebbinghaus

  • Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer

    Ryan B. Corcoran;Thierry Andre;Chloe E. Atreya;Jan H.M. Schellens

  • A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma

    Gregory L. Beatty;Drew A. Torigian;E. Gabriela Chiorean;Babak Saboury

  • A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme

    Myrna R. Rosenfeld;Xiaobu Ye;Jeffrey G. Supko;Serena Desideri

  • Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients

    Mark Sausen;Jillian Phallen;Vilmos Adleff;Siân Jones

  • Etoposide (VP-16-213). Current status of an active anticancer drug.

    P J O'Dwyer;B Leyland-Jones;M T Alonso;S Marsoni

Frequent Co-Authors

Keith T. Flaherty
Keith T. Flaherty Harvard University
Al B. Benson
Al B. Benson Northwestern University
Stanley R. Hamilton
Stanley R. Hamilton City Of Hope National Medical Center
Thomas C. Hamilton
Thomas C. Hamilton Fox Chase Cancer Center
Robert F. Ozols
Robert F. Ozols Fox Chase Cancer Center
Mark A. Rosen
Mark A. Rosen University of Pennsylvania
Paul J. Catalano
Paul J. Catalano Harvard University
Daniel G. Haller
Daniel G. Haller University of Pennsylvania
Carlos L. Arteaga
Carlos L. Arteaga The University of Texas Southwestern Medical Center
Angela DeMichele
Angela DeMichele University of Pennsylvania

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Medicine in the USA opens doors to a wide range of healthcare careers. For students seeking flexibility and affordability, online degrees in the medical field are becoming increasingly popular. Roles such as medical coder, nurse, nurse practitioner, or nurse educator are now more accessible than ever through accredited online programs.

Medical coding certification online programs provide a fast track into healthcare administration, a field in high demand for accuracy and up-to-date knowledge of billing systems. For those aiming to become advanced practice nurses, the cheapest online FNP program options make it easier to balance study, work, and family commitments.

Aspiring registered nurses can find affordable nursing programs online, helping to reduce the financial barrier to entry in this respected profession. For nurses interested in leadership or academic roles, a doctorate in nursing education online programs unlocks further career advancements without the need to relocate.

These accessible online learning paths can help you reach your healthcare career goals while maintaining flexibility and controlling costs.

Best Scientists Citing Peter J. O'Dwyer

Trending Scientists

Recently Published Articles